Navigation Links
University of Kentucky spinoff licensed to develop Alzheimer's treatment
Date:9/22/2011

LEXINGTON, Ky. (Sept. 21, 2011) -- CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

According to a released statement from Hawthorn Pharmaceuticals, a commercial-stage specialty drug company, research indicates hawAD14 significantly decreases production of amyloid beta (Aβ) the major component of senile plaques and alters proteins associated with hyperphosphorylation of tau which is associated with neurofibrillary tangles present in Alzheimer's disease.

"In terms of the discovery's uniqueness, it's one of only a few programs in the world demonstrating multiple protective effects against the predominant pathogenic pathways of Alzhiemer's disease," said Rob Lewis, chief scientific officer at Hawthorn. "We are in the process of completing necessary preclinical studies in order to file an IND (investigational new drug) with the FDA," said Hawthorn CEO Max Draughn.

CoPlex co-founder and CEO John Beran said, "University of Kentucky researchers and CoPlex founding scientists Mark Lovell and Bert Lynn discovered an aberrant protein complex linked to Alzheimer's which gave them a unique approach to begin to interrupt pathogenic mechanisms associated with the disease. They evaluated multiple compounds to see if they could minimize events on the path toward Alzheimer's and the leading candidate was hawAD14."

"The discovery of hawAD14 may be the most promising research of our professional careers," said Mark Lovell, Jack & Linda Gill Professor of Chemistry and research faculty with the UK Sanders-Brown Center on Aging. "We are extremely excited by the potential this compound holds to slow the progression of Alzhiemer's and significantly improve the lives of individuals impacted by this terrible disease." Lovell worked as a graduate student and postdoctoral scholar under the direction of Dr. William D. Ehmann and the late Sanders-Brown founder Dr. William R. Markesbery.

UK chemistry colleague and CoPlex co-founder Bert Lynn said, "While developing haw AD14, we have gained insight into possible biochemical pathways leading to neurodegeneration and are using this information to identify additional active compounds for other neurodegenerative diseases." In addition to being a professor in the Department of Chemistry, Lynn is also a Sanders-Brown Center on Aging faculty associate and director of the UK Mass Spectrometry Facility in the ASTeCC campus incubator.

Lovell and Lynn have partnered with Beran on another University of Kentucky spinoff company Scout Diagnostics. The Scout technology measures levels of a novel protein biomarker the same aberrant protein complex discovered and used to develop hawAD14 and other compounds through CoPlex.

According to Beran, the current Scout prototype test detects this biomarker which is tied to the progression of Alzheimer's from its earliest manifestation as mild cognitive impairment. "This is a point early enough in the progression of the disease that next-generation therapeutics may offer the prospect of slowing further cognitive decline."

"Imagine going for a check up, having blood drawn and being placed on a safe therapeutic drug that will slow the progress of Alzheimer's so that you never experience its symptoms. This is our hope for both technologies," said Beran, who was introduced to Lovell and Lynn by their chemistry department colleague John Anthony in 2006. Anthony and Beran are co-founders of Outrider Technologies.

"The CoPlex technology is moving so fast that it is hard to predict the limits on its application," said Beran, who plans to work with Hawthorn Pharmaceuticals to develop additional drug candidates for other neurologic disorders. "We believe what Mark and Bert have uncovered will lead to better treatments for these vexing diseases."

The Scout Diagnostics' technology can be applied in different situations where it is important to know whether a patient is beginning to develop Alzheimer's such as in clinical trials. "It is perfectly suited for a first-in-category blood test for Alzheimer's which would be considered an in vitro diagnostic medical device," said Beran. He is working with several companies that are interested in developing this technology.

Beran has also worked closely with the University of Kentucky Office for Commercialization & Economic Development, and both CoPlex Therapeutics and Scout Diagnostics are located in the ASTeCC campus incubator, managed by the UKCED office. "Between lab space, relationships with investors and networking gatherings, I've been able to champion my spinoff companies and their technologies forward," said Beran. "Len Heller has a great mind for business and is a mentor to me."

"We are all very pleased that CoPlex Therapeutics and Scout Diagnostics are moving closer to making significant contributions to the early detection and treatment of Alzheimer's disease," said Beran.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert  

Related medicine news :

1. University Hospitals Case Medical Center awarded 2011 fellowship awards for pain medicine, epilepsy
2. Wayne State University partners with Toyota on safety research
3. Wayne State University researcher to study spinal muscular atrophy
4. Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial
5. First US patient receives specially processed donor lungs at the University of Maryland
6. University of Houston hosts book symposium on Making War and Minting Christians, Sept. 8
7. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
8. University of Kentucky Sanders-Brown Center on Aging receives $7 million from NIA
9. Major advanced cancer study to be led by Uppsala University
10. Baylor University study finds consequences of co-worker rudeness are far-reaching
11. University Hospitals Neuromuscular Center EMG labs awarded accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
University of Kentucky spinoff licensed to develop Alzheimer's treatment
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... is the first organization with pending recognition status from the Centers for Disease ... via group telehealth classes and live video conferencing. , The DPP resulted ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of ... location as an interventional pain management physician. He brings a wealth of pain ... migraine headaches, and significant experience in spinal cord stimulation for chronic pain. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/4/2017)... The search for test results that can ... has long been the goal of healthcare providers and ... the largest meeting of lab professionals and IVD firms ... firm Kalorama Information.  The firm said scores of companies ... supplies and software were at the American Association for ...
Breaking Medicine Technology: